Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™

Orlo H. Clark, Jaffer Ajani, Al B. Benson, David Byrd, Gerard M. Doherty, Paul F. Engstrom, David S. Ettinger, John F. Gibbs, Martin J. Heslin, Fouad Kandeel, Anne Kessinger, Matthew H. Kulke, Larry Kvols, Albert A. Nemcek, John A. Olson, Thomas W. Ratliff, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.

Original languageEnglish (US)
Pages (from-to)102-138
Number of pages37
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number2
StatePublished - Feb 2006


  • Carcinoma
  • Islet cell cancer
  • MEN-1
  • MEN-2
  • Multiple endocrine neoplasia
  • NCCN Clinical Practice Guidelines
  • Neuroendocrine tumors
  • Pheochromocytoma

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™'. Together they form a unique fingerprint.

Cite this